TAG Inhibitors

The chemical class of TAG inhibitors comprises compounds that target various enzymes and signaling pathways involved in TAG synthesis and metabolism. One key target is pancreatic lipase, inhibited by Orlistat, which reduces the hydrolysis of dietary triglycerides and thereby inhibits TAG synthesis. Fibrates, such as Fenofibrate and Gemfibrozil, activate peroxisome proliferator-activated receptor alpha (PPARα), promoting the upregulation of genes involved in fatty acid oxidation and TAG clearance from the bloodstream. Additionally, statins, including Simvastatin and Atorvastatin, inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, leading to reduced cholesterol synthesis and indirectly affecting TAG production.

Another approach to inhibiting TAG synthesis is through the modulation of carbohydrate metabolism. Acarbose inhibits alpha-glucosidase, delaying carbohydrate digestion and absorption, which can lead to reduced TAG synthesis due to decreased availability of substrates for lipogenesis. Niacin, also known as vitamin B3, inhibits diacylglycerol acyltransferase (DGAT), an enzyme involved in TAG synthesis, leading to decreased hepatic TAG production. Omega-3 fatty acids, found in fish oil supplements, downregulate lipogenic genes while promoting fatty acid oxidation, resulting in reduced TAG synthesis. Resveratrol, a polyphenol found in grapes and red wine, activates SIRT1, which inhibits sterol regulatory element-binding protein 1c (SREBP-1c), a transcription factor involved in TAG synthesis. These compounds collectively offer potential strategies for modulating TAG metabolism and may have implications for managing conditions associated with dysregulated lipid metabolism.